Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
LT-4001 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 October 2026
LT-4001: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Ortataxel Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 October 2026
Ortataxel: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Teprotumumab(bx-biopharm) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 October 2026
Teprotumumab(bx-biopharm): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risk
9 min read
Rabeximod Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 October 2026
Rabeximod: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Narmafotinib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 October 2026
Narmafotinib: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Pynegabine Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 October 2026
Pynegabine: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Huoxuexiaoyi granules Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 October 2026
Huoxuexiaoyi granules: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
SPN-821 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 October 2026
SPN-821: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
KH-001 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 October 2026
KH-001: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Shutang Granules Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 October 2026
Shutang Granules: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
KB-105 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 October 2026
KB-105: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Zampilimab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 October 2026
Zampilimab: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.